source
- Novartis reports Phase 3 success for MS pill remibrutinib, beats Aubagio and shows no liver safety issuesNovartis announced that its BTK inhibitor remibrutinib met primary endpoints in two Phase 3 trials in patients with relapsing multiple sclerosis. The studies showed the drug reduced annualized rel…
- GSK to begin Phase 3 trial of mRNA seasonal flu vaccine after strong Phase 2 resultsGSK announced it will start a Phase 3 study of its mRNA vaccine targeting seasonal influenza. The move follows Phase 2 data that showed the candidate produced higher immune responses than traditio…